| TMC Life Sciences (0101.KU) - Malaysia | ||
| (2nd) quarter ended Dec 31: | ||
| Figures Are In Ringgit $(MYR.AU)$. | ||
| 2024 | 2023 | |
| Revenue | 80,426,000 | 93,783,000 |
| PreTax Profit | -493,000 | 19,680,000 |
| Net Profit | -947,000 | 14,524,000 |
| Earnings Per Share | -0.05 Sen | 0.83 Sen |
| Dividend | 0.00 Sen | 0.00 Sen |
| 6 months ended Dec 31: | ||
| Revenue | 162,393,000 | 186,221,000 |
| PreTax Profit | 3,966,000 | 39,823,000 |
| Net Profit | 1,989,000 | 29,664,000 |
| Earnings Per Share | 0.11 Sen | 1.70 Sen |
| Dividend | 0.00 Sen | 0.00 Sen |
(END) Dow Jones Newswires
February 10, 2025 04:24 ET (09:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。